Several lines of evidence suggest that TKIs administered to CML patients upregulate interferon γ (IFNγ) production, which may counteract the anti-tumorigenic effects of the therapy. This evidence concerns the gene IFNG and chronic myelogenous leukemia, BCR-ABL1 positive.